Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production
Microvesicles (MVs) are released by immune cells especially of the myeloid lineage upon stimulation with ATP on its cognate receptor P2X7, both in physiological and pathological conditions. In multiple sclerosis (MS) the role of MVs remains little investigated. We aimed to compare the release of MVs...
Main Authors: | Maria Blonda, Antonella Amoruso, Roberta Grasso, Valeria Di Francescantonio, Carlo Avolio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fneur.2017.00422/full |
Similar Items
-
TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)
by: E. V. POPOVA, et al.
Published: (2016-12-01) -
Microvesicles: what is the role in multiple sclerosis?
by: Tiziana eCarandini, et al.
Published: (2015-05-01) -
Patients monitoring during treatment with Teriflunomide (ORP-41)
by: Nahid Hoseini Nejad Mir
Published: (2023-01-01) -
ORAL DRUGS FOR PATHOGENETIC TREATMENT OF MULTIPLE SCLEROSIS
by: E. V. Popova, et al.
Published: (2017-07-01) -
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
by: Carlo Tornatore, et al.
Published: (2022-02-01)